---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-042122"
form_type: "8-K"
ticker: "APUS"
cik: "0001894525"
company_name: "Apimeds Pharmaceuticals US, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:38:38.627152+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Apimeds Pharmaceuticals US completes $13.5M IPO; starts trading on NYSE American

## Summary
- IPO of 3,375,000 shares at $4.00/share; gross proceeds $13.5M.
- Proceeds to fund Phase III knee osteoarthritis trial, MS study, manufacturing, working capital.
- Convertible notes of $772,545 converted into 297,133 shares at $2.60/share.
- Underwriters granted 45-day option for 506,250 additional shares and warrants for 168,750 shares.
- Trading began May 9, 2025 on NYSE American under symbol APUS.

## SEC filing metadata
- accession: 0001213900-25-042122
- form_type: 8-K
- ticker: APUS
- cik: 0001894525
- company_name: Apimeds Pharmaceuticals US, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894525/000121390025042122/0001213900-25-042122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894525/000121390025042122/ea0241711-8k_apimeds.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-042122
- JSON: https://secwatch.observer/filing/0001213900-25-042122.json
- Plain text: https://secwatch.observer/filing/0001213900-25-042122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.